Uremia alters HDL composition and function.
暂无分享,去创建一个
T. Stojaković | Veronika Binder | G. Marsche | C. Wadsack | A. Heinemann | M. Holzer | R. Birner‐Gruenberger | Dalia El-Gamal
[1] P. Stiegler,et al. Protein carbamylation renders high-density lipoprotein dysfunctional. , 2011, Antioxidants & redox signaling.
[2] A. Vaughan,et al. ATP binding cassette G1-dependent cholesterol efflux during inflammation1 , 2011, Journal of Lipid Research.
[3] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[4] P. Stenvinkel,et al. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease , 2010, Journal of internal medicine.
[5] M. Phillips,et al. High-density lipoprotein heterogeneity and function in reverse cholesterol transport , 2010, Current opinion in lipidology.
[6] N. Vaziri,et al. HDL metabolism and activity in chronic kidney disease , 2010, Nature Reviews Nephrology.
[7] J. Danesh,et al. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.
[8] P. Giral,et al. Stimulation of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human Macrophages Is ABCA1-Dependent but ABCG1-Independent , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[9] H. Moradi,et al. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. , 2009, Kidney international.
[10] D. Rader,et al. Update on strategies to increase HDL quantity and function , 2009, Nature Reviews Cardiology.
[11] A. Kontush,et al. Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[12] H. Scharnagl,et al. Plasma-Advanced Oxidation Protein Products Are Potent High-Density Lipoprotein Receptor Antagonists In Vivo , 2009, Circulation research.
[13] Muredach P. Reilly,et al. Inflammation Impairs Reverse Cholesterol Transport In Vivo , 2009, Circulation.
[14] A. Vaughan,et al. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux* , 2009, Journal of Lipid Research.
[15] N. Webb,et al. HDL Remodeling During the Acute Phase Response , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[16] A. Bobik. Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. , 2008, Circulation.
[17] A. Jurek,et al. The ability of HDL to inhibit VCAM-1 expression and oxidized LDL uptake is impaired in renal patients. , 2008, Clinical biochemistry.
[18] G. Watts,et al. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.
[19] D. Sviridov,et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. , 2008, Journal of atherosclerosis and thrombosis.
[20] A. Tall,et al. Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.
[21] K. Kalantar-Zadeh,et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. , 2007, Kidney international.
[22] H. Ginsberg,et al. Lipoprotein metabolism in chronic renal insufficiency , 2007, Pediatric Nephrology.
[23] Sina A. Gharib,et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.
[24] J. Raynes,et al. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. , 2007, The Biochemical journal.
[25] K. Siamopoulos,et al. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[26] K. Resing,et al. Comparison of Label-free Methods for Quantifying Human Proteins by Shotgun Proteomics*S , 2005, Molecular & Cellular Proteomics.
[27] A. Zalewski,et al. Role of Lipoprotein-Associated Phospholipase A2 in Atherosclerosis: Biology, Epidemiology, and Possible Therapeutic Target , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[28] Per Leanderson,et al. Lipoproteomics II: Mapping of proteins in high‐density lipoprotein using two‐dimensional gel electrophoresis and mass spectrometry , 2005, Proteomics.
[29] P. Linsel-Nitschke,et al. HDL as a target in the treatment of atherosclerotic cardiovascular disease , 2005, Nature Reviews Drug Discovery.
[30] R. Heller,et al. 2-Chlorohexadecanal Derived From Hypochlorite-Modified High-Density Lipoprotein–Associated Plasmalogen Is a Natural Inhibitor of Endothelial Nitric Oxide Biosynthesis , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[31] P. Barter,et al. Antiinflammatory Properties of HDL , 2004, Circulation research.
[32] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[33] John R Yates,et al. Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. , 2003, Analytical chemistry.
[34] M. Adachi,et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. , 2003, Kidney international.
[35] P. Stenvinkel. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. , 2003, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[36] Peter Stenvinkel,et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. , 2002, Kidney international.
[37] S. Lestavel,et al. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[38] L. Havekes,et al. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[39] R. Krauss,et al. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. , 1999, Biochimica et biophysica acta.
[40] Y. Marcel,et al. Specific Phospholipid Association with Apolipoprotein A-I Stimulates Cholesterol Efflux from Human Fibroblasts , 1996, The Journal of Biological Chemistry.
[41] A. von Eckardstein,et al. Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. , 1991, The Journal of clinical investigation.
[42] G. Coetzee,et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. , 1986, The Journal of biological chemistry.
[43] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[44] G. Kaysen. Lipid and lipoprotein metabolism in chronic kidney disease. , 2009, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[45] Rebekah L. Gundry,et al. Investigation of an albumin‐enriched fraction of human serum and its albuminome , 2007, Proteomics. Clinical applications.
[46] Farhad Rezaee,et al. Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.